| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Sichuan Goldstone Asia Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.53 |
| 52 Week High | CN¥16.12 |
| 52 Week Low | CN¥6.89 |
| Beta | 0.33 |
| 1 Month Change | -5.54% |
| 3 Month Change | -6.16% |
| 1 Year Change | -44.79% |
| 3 Year Change | -2.63% |
| 5 Year Change | 5.57% |
| Change since IPO | 101.76% |
Recent News & Updates
Shareholder Returns
| 300434 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.2% | -1.2% | -0.4% |
| 1Y | -44.8% | -12.7% | -12.6% |
Return vs Industry: 300434 underperformed the CN Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: 300434 underperformed the CN Market which returned -11.8% over the past year.
Price Volatility
| 300434 volatility | |
|---|---|
| 300434 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 300434 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300434's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,962 | Baokang Wei | www.goldstone-group.com |
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment. The company produces, installs, and maintains special equipment.
Sichuan Goldstone Asia Pharmaceutical Inc. Fundamentals Summary
| 300434 fundamental statistics | |
|---|---|
| Market cap | CN¥3.43b |
| Earnings (TTM) | CN¥72.56m |
| Revenue (TTM) | CN¥1.15b |
47.2x
P/E Ratio3.0x
P/S RatioIs 300434 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300434 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.15b |
| Cost of Revenue | CN¥476.09m |
| Gross Profit | CN¥676.11m |
| Other Expenses | CN¥603.55m |
| Earnings | CN¥72.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 58.68% |
| Net Profit Margin | 6.30% |
| Debt/Equity Ratio | 4.6% |
How did 300434 perform over the long term?
See historical performance and comparison